跳到正文
原文
Endpoints News 生物医药· Ryan Cross·· 2 天前AI 评分47

Priavoid 阿尔茨海默药 PRI-002 Phase 2 研究失败

#CTAD26: Priavoid’s amyloid-detangling pill PRI-002 fails Phase 2 study in Alzheimer’s

AI 导读

德国生物科技公司 Priavoid 针对阿尔茨海默病开发的口服淀粉样蛋白解聚药物 PRI-002,其 Phase 2 临床试验未能达到预期目标。来源为 Endpoints News 对 #CTAD26 会议的报道,正文其余内容受付费墙限制未能完整显示。

正文

BOSTON — For near­ly a decade, the Ger­man biotech start­up Pri­avoid has been work­ing on a pill to break up small clumps of amy­loid pro­teins that …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news